



The goal of hepatitis C virus (HCV) treatment is a cure (when there is no HCV in a person’s bloodstream 12 weeks after treatment is finished).

What is Mavyret? Mavyret (also known as Maviret) is a fixed-dose combination of two HCV-fighting drugs (glecaprevir and pibrentasvir) in one pill. In the United States, Mavyret is approved for people with all hepatitis C genotypes (1 – 6) who are 18 years of age and older.

How is Mavyret used? Mavyret is taken once daily, given as 3 tablets, with food, for 8, 12, or 16 weeks. People who have compensated cirrhosis, or cirrhosis without liver-related symptoms, will need to take Mavyret for 12 or 16 weeks. The effectiveness of the treatment depends on whether a person has cirrhosis and previous HCV treatment history. Mavyret has similar efficacy across genotypes in treatment-naïve patients.

FDA-Recommended Treatment Length and Cure Rates in Clinical Trials *

Genotype 1, 2, 3, 4, 5 and 6, no cirrhosis	+ compensated cirrhosis
8 weeks: 98%	12 weeks: 99%
Genotype 3, treatment experience with pegylated interferon and/or ribavirin:	+ compensated cirrhosis
16 weeks: 95%	16 weeks: 96%

*Cure rates in clinical trials are higher than in the general population because the people in trials are usually healthier and receive extra monitoring and support.

The most important thing a person can do to be cured is take all your HCV medication—this is called **adherence**. This lowers the risk that the virus will develop resistance to treatment and increases the chances of cure.

What is drug resistance? Each day, HCV makes billions of copies of itself. Some copies are not the same as the original virus. They may have changes (called **mutations**) that can stop hepatitis C drugs from working. If people miss doses of their treatment, HCV gets a chance to reproduce—and some of the copies may be resistant to HCV treatment.

Some people have drug resistance even though they have never been on hepatitis C treatment, but many can be cured anyway. Most people who are not cured have resistance to one or more of the HCV drugs they have taken. Resistance to some hepatitis C drugs can disappear within months, but it can also last for years and may limit re-treatment options. Some people who were treated with—but not cured by—Mavyret have been re-treated with—and cured by—a combination of drugs.

Mavyret and age, gender, and race/ethnicity: In clinical trials, cure rates did not differ by age (18–88 years), gender, or race/ethnicity.

Side effects from Mavyret: Talk with your health care provider about possible side effects and how they can be managed. In clinical trials of Mavyret, the most common side effects were headache, fatigue, and nausea, usually mild.

Does Mavyret work with HIV drugs? Mavyret cannot be taken with certain HIV drugs. Coadministration with atazanavir or rifampin is contraindicated. See **Mavyret and Other Treatments** below for more information. .

Mavyret and other medications: Mavyret should not be used with certain drugs. Combining medications can increase or decrease drug levels (called **drug-drug interactions**). An increase can make side effects worse. A decrease can prevent a drug from working, putting people at risk for resistance or not being cured.

Mavyret should not be used in people taking anticonvulsants (carbamazepine, phenobarbital, phenytoin) and antibacterials (rifampin). Mavyret also should not be used in people taking ethinyl estradiol-containing medications such as oral contraceptives. Do not take St. John’s wort herbal supplements with Mavyret, and tell your doctor if you are taking statins or medications for cancer, seizures, bacterial infections, or heartburn/acid reflux.

Talk with your health care provider before starting or stopping any medications, supplements, or herbal remedies.

More information is available in Mavyret’s prescribing information (https://www.rxabbvie.com/pdf/mavyret_pi.pdf).

Mavyret and Other Treatments

HIV protease inhibitors	
Darunavir/lopinavir/ritonavir (Prezista, Kaletra, Albuvirtide, Norvir)	Do not use Mavyret with medications containing darunavir, lopinavir, and/or ritonavir.
Atazanavir (Reyataz)	Do not use Mavyret with medications containing atazanavir.
HIV non-nucleoside reverse transcriptase inhibitors	
Efavirenz (Sustiva, Atripla)	Do not use Mavyret with medications containing efavirenz.
Antibacterials (for tuberculosis)	
Rifampin	Contraindication. Do not use Mavyret with medications containing rifampin.

Storing Mavyret: Keep Mavyret at room temperature (below 30°C [86°F]).

Mavyret in people with hepatitis B: Mavyret is not recommended for patients coinfecting or previously infected with hepatitis B virus (HBV). Mavyret has been linked to risk of HBV re-activation in coinfecting patients as well as patients with previously resolved HBV infection. Patients with HBV or past infection with HBV should ask their doctor whether Mavyret is right for them.

Mavyret in people with kidney disease: Mavyret can be used by people with mild to severe kidney disease. Patients with severe kidney disease or on dialysis who also have cirrhosis should ask their doctor whether Mavyret is right for them.

Mavyret in people with cirrhosis: Mavyret is contraindicated when used in persons with decompensated cirrhosis (Child-Pugh Class C) and not recommended in persons with Child-Pugh Class B. HCV treatment guidelines recommend that people with serious liver damage (Child-Pugh Class B or C) be treated by a specialist.

Mavyret during pregnancy or nursing and in children: It is not known whether Mavyret causes harm to unborn babies or passes into breast milk. If you are pregnant or breast feeding, or planning for either, talk with your health care provider about the risks and benefits of HCV treatment. Mavyret has not been tested in children younger than 18 years old.

Access to Mavyret may be restricted by public and private payers. The criteria differ depending on the type of coverage and the state in which the coverage is issued. Mavyret Patient Support is AbbVie’s patient assistance program for Mavyret. People with private insurance may be eligible for assistance with copayments. Uninsured people may be eligible for medication at no charge. Information about Mavyret Patient Support is available online at <https://www.mavyret.com/hcp/patient-support>. Information about Mavyret Patient Support is also available by phone at 1-877-628-9738, Monday through Friday between 8:00 a.m. and 8:00 p.m. (Eastern Time).

This fact sheet is current as of May 2019. Always check for updated information.